ReviewBeilstein journal of nanotechnology2026
Breaking barriers: nanosystems to overcome solubility and permeability challenges of second-generation tyrosine kinase inhibitors.
Review in Beilstein journal of nanotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Second-generation tyrosine kinase inhibitors (TKIs) - bosutinib, nilotinib, and dasatinib - demonstrate therapeutic efficacy across various chronic malignancies, including chronic myelogenous leukaemia, acute lymphoblastic leukaemia, breast cancer, lung cancer, pancreatic cancer, and hepatocellular cancer. However, in the Biopharmaceutics Classification System, they are classified as class-II and class-IV drugs, exhibiting poor, pH-dependent solubility and low permeability, leading to poor and unpredictable bioavailability and variable plasma concentrations, compromising their clinical efficacy. Even though the oral route is the most widely accepted mode of administration, systematic analysis of the formulation database revealed that the conventional formulations encounter biopharmaceutical barriers limiting the therapeutic performance of drugs. Hence, this review examines nanotechnology-driven solutions that may improve the second-generation TKIs' biopharmaceutical properties for better therapeutic performance by enhancing their pharmacokinetic properties. Various nanosystems, such as solid lipid nanoparticles, nanostructured lipid carriers, polymeric micelles, polymeric nanoparticles, nanocrystals, self-nanoemulsifying drug delivery systems, and nanosuspensions, have been developed to enhance solubility, permeability, and bioavailability. The nanoformulations achieved variable improvements in solubility and bioavailability (1.5- to 38-fold) compared with free drugs, depending on surface characteristics, carrier composition, and drug properties. This was possible through tailored particle size, drug loading, and precise drug release kinetics via various mechanisms. This review consolidates the evidence from peer researchers on positioning nanoformulations as a transformative tool to improve the efficacy of second-generation TKIs. Critical evaluation was performed based on solubility/permeability enhancement potential, safety profile, toxicological burden, long-term stability, scalability, and feasibility for clinical transition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.